The continuous flow in jet-induced fountains inspired Nourredine Frid, CEO at Cardiatis (Isnes), to apply the theory of fluid mechanics to blood vessels. By converting [...]
Advances in novel technologies and manufacturing practices are essential to building and maintaining a global leadership position. With this rationale, the European
In contrast to the chemical industry, where many commercial processes are continuous processes, most processes in the biopharmaceutical industry are batch processes. The latter are generally slower and more expensive than their continuous counterparts. Continuous processes are also more reproducible, and the quality is more consistent. Despite these proven advantages, continuous processes are seldom found in the biopharmaceutical industry. As many improvements on process units are being developed, biopharmaceutical parties are becoming more and more aware of the added value of continuous bioprocessing. Pall Life Sciences presents a new downstream technology that is designed to increase purification efficiency using a continuous chromatography system.
Engineering simulation is the next big thing in medical development. It can be used to design, rethink and optimize devices before going into clinical trials. These simulations can also be used as an invaluable tool in determining which surgical technique is best to use on a specific patient. Additionally, it allows scientists and physicians to predict the route of a drug through the body. Because it only involves the calculating power of a computer, it is a fast and cheap alternative providing an enormous competitive advantage for the companies that use it. We spoke with Thierry Marchal, Global Industry Director for healthcare at ANSYS, a world leader in this technology, about this exciting revolution.
In 2008, UGent spin-off ProDigest opened its doors. The company was built around a machine called the SHIME®, an in vitro model for the entire human gastrointestinal tract, complete with stomach and small and large intestines. The immediate interest from the food industry quickly made ProDigest a household name in its niche market. Since its establishment, ProDigest has significantly expanded its technology and activities and has taken on the pharmaceutical and veterinarian industries as additional partners.
The continuous flow in jet-induced fountains inspired Nourredine Frid, CEO at Cardiatis (Isnes), to apply the theory of fluid mechanics to blood vessels. By converting [...]
Advances in novel technologies and manufacturing practices are essential to building and maintaining a global leadership position. With this rationale, the European
In contrast to the chemical industry, where many commercial processes are continuous processes, most processes in the biopharmaceutical industry are batch processes. The latter are generally slower and more expensive than their continuous counterparts. Continuous processes are also more reproducible, and the quality is more consistent. Despite these proven advantages, continuous processes are seldom found in the biopharmaceutical industry. As many improvements on process units are being developed, biopharmaceutical parties are becoming more and more aware of the added value of continuous bioprocessing. Pall Life Sciences presents a new downstream technology that is designed to increase purification efficiency using a continuous chromatography system.
Engineering simulation is the next big thing in medical development. It can be used to design, rethink and optimize devices before going into clinical trials. These simulations can also be used as an invaluable tool in determining which surgical technique is best to use on a specific patient. Additionally, it allows scientists and physicians to predict the route of a drug through the body. Because it only involves the calculating power of a computer, it is a fast and cheap alternative providing an enormous competitive advantage for the companies that use it. We spoke with Thierry Marchal, Global Industry Director for healthcare at ANSYS, a world leader in this technology, about this exciting revolution.
In 2008, UGent spin-off ProDigest opened its doors. The company was built around a machine called the SHIME®, an in vitro model for the entire human gastrointestinal tract, complete with stomach and small and large intestines. The immediate interest from the food industry quickly made ProDigest a household name in its niche market. Since its establishment, ProDigest has significantly expanded its technology and activities and has taken on the pharmaceutical and veterinarian industries as additional partners.